Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathway

    ... The effects of erythropoietin on osteoblasts and bone formation are controversially ... myelodysplastic syndromes often display excessively high erythropoietin level, we aimed to analyze the effect of erythropoietin on ...

    Research Article last updated 11/08/2017 - 8:52am.

  2. Pro-inflammatory proteins S100A9 and TNFα suppress erythropoietin elaboration in myelodysplastic syndromes

    ...

    Research Article last updated 10/20/2017 - 9:16am.

  3. Erythropoietin administration is associated with improved T-cell properties in patients with myelodysplastic syndromes

    ... the disease. Here we show effects of recombinant human erythropoietin (rHuEPO) on T cell (CD4+, CD8+ and CD4+CD25+) number ...

    Research Article last updated 12/09/2016 - 3:05pm.

  4. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors

    ... erythropoiesis-stimulating agents (ESAs) such as erythropoietin (EPO) and mimetics are applied as first-line therapy in a ...

    Research Article last updated 10/23/2017 - 11:08am.

  5. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond

    ... restores effective erythropoiesis via enhancement of erythropoietin (EPO) receptor-initiated transcriptional response arising ...

    Research Article last updated 10/23/2017 - 10:58am.

  6. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors

    ... erythropoiesis-stimulating agents (ESAs) such as erythropoietin (EPO) and mimetics are applied as first-line therapy in a ...

    Research Article last updated 10/02/2017 - 10:10am.

  7. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond

    ... restores effective erythropoiesis via enhancement of erythropoietin (EPO) receptor-initiated transcriptional response arising ...

    Research Article last updated 10/02/2017 - 9:54am.

  8. Foundation Update - April 2016

    ... as relatively low risk. I have been treated with erythropoietin (Procrit®), G-CSF, (Neupogen®), azacitidine , ...

    Article last updated 10/09/2017 - 2:57pm.

  9. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

    ... vs <4 red blood cell units per 8 weeks); pre-study serum erythropoietin concentration (<200 IU/L, 200-500 IU/L, and >500 IU/L); ...

    Research Article last updated 09/18/2017 - 1:38pm.

  10. Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.

    ... of treatment with deferasirox combined with erythropoietin vs. erythropoietin alone on erythropoiesis in patients with low- and ...

    Clinical Trial last updated 04/27/2016 - 12:52pm.